Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep (NASDAQ: IMMP) reported Q4 FY26 activities, highlighting new clinical, IP and financial developments. A pooled analysis of five efti trials (592 patients, four tumour types) showed increased lymphocyte counts with efti plus standard of care and a 7.7‑month median overall survival benefit for biological responders versus non‑responders.
The TACTI‑004 Phase III 1L NSCLC trial was discontinued after interim futility; efti arm ORR was 42.9% vs 55.1% for control, with no new safety signals and root‑cause work ongoing. INSIGHT‑003 reported median OS of 30.9 months, EFTISARC‑NEO met its primary immune‑activation objective and efti received FDA orphan drug designation in soft tissue sarcoma. First‑in‑human IMP761 data met its primary safety endpoint and showed significant pharmacodynamic activity. Immutep ended the quarter with A$68.87 million in cash, cash equivalents and term deposits, has implemented cost‑reduction measures, and expects its cash runway to extend into H1 CY28.
Immutep (NASDAQ: IMMP) announced that an abstract from the investigator-initiated Phase II EFTISARC-NEO trial of its MHC Class II agonist eftilagimod alfa (efti) in soft tissue sarcoma has been accepted as an ePoster for the ESMO Congress 2026, held 23–27 October 2026 in Madrid, Spain.
The abstract focuses on health-related quality of life (HRQoL) during neoadjuvant treatment with efti, pembrolizumab and radiotherapy. It will be available online on the ESMO website from 00:05 CEST on 19 October 2026 (Presentation #3788eP), with the presentation later accessible on Immutep’s website. The first author is Dr. Pawel Teterycz from the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw.
Immutep (NASDAQ: IMMP) announced that the United States Patent and Trademark Office has granted a new patent (No. 12,673,088) titled “Combined Preparations for the Treatment of Cancer or Infection.” This is the fourth U.S. patent in Immutep’s series covering eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors.
The patent protects methods for treating cancer using efti with anti-PD-1 or anti-PD-L1 antibodies, or their fragments, and expires on 20 January 2036. According to Immutep, the grant strengthens its intellectual property estate for efti combinations and supports future development and business development opportunities.
Immutep (NASDAQ: IMMP) reported mature overall survival data from the INSIGHT-003 Phase I trial of eftilagimod alfa (efti) plus KEYTRUDA and chemotherapy in 1st line non-squamous NSCLC (N=51). Median overall survival (mOS) reached 30.9 months in both the overall population and patients with PD-L1 TPS <50% (N=47), and 37.8 months in TPS ≥50% (N=4). Approximately 92% of patients had TPS <50%, a group with significant unmet need, and outcomes continue to compare favourably with a 22.0‑month mOS historical benchmark for anti‑PD‑1 plus doublet chemotherapy. No new safety signal was seen.
Immutep also updated on the discontinued TACTI‑004 Phase III 1L NSCLC trial, where interim futility analysis showed an ORR of 42.9% for the efti arm versus 55.1% for control (N=173). Preliminary immune monitoring indicates a markedly different immune activation profile versus prior efti studies and INSIGHT‑003. Root cause analysis, including manufacturing factors, is ongoing, with further results expected in Q3 CY2026.
Immutep (NASDAQ: IMMP) reported positive interim Phase I data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. In healthy volunteers, the randomized, placebo-controlled study met its primary safety endpoint and showed favourable tolerability across single ascending doses.
IMP761 demonstrated statistically significant pharmacodynamic activity at 7 mg/kg (p = 0.029) in a validated KLH immune challenge model, reduced local inflammation, and attenuated T-cell activity. Pharmacokinetics support once-every-4-weeks dosing, backing progression toward Phase II. Data are being presented at EULAR 2026 in London.
Immutep (NASDAQ: IMMP) reported pooled results from five clinical trials of eftilagimod alfa (efti) plus standard-of-care in 5,922 late-stage cancer patients. Efti 30 mg SC increased absolute lymphocyte count (ALC) versus SOC alone, and ALC responders in the efti+SOC group showed a median overall survival improvement of +7.7 months (p=0.00171) over non-responders.
Efti treatment was also linked to higher TH1 biomarkers and enhanced T-cell function, suggesting broad immune activation associated with improved clinical benefit across multiple tumor types. Separately, Immutep discontinued the TACTI-004 Phase III trial in March 2026 after an interim futility analysis.
Immutep (NASDAQ: IMMP / ASX: IMM) announced discontinuation of the TACTI-004 Phase III 1L NSCLC trial after an IDMC-recommended interim futility analysis, with a root cause review underway through Q3 CY2026. Cash and term deposits total A$110.6 million, providing runway into H1 CY2028; IMP761 Phase I shows favourable safety and moves to MAD, with data due at EULAR June 2026. The Company expects a US$10 million payment obligation to Dr. Reddy’s in June 2026 and is implementing cost reductions while winding down TACTI-004.
Immutep (NASDAQ: IMMP) received a Nasdaq notice that its American Depositary Shares failed to meet the US$1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days ended April 24, 2026.
Nasdaq has given an initial 180-calendar-day compliance period through October 26, 2026, during which Immutep must achieve a closing ADS bid of at least US$1.00 for ten consecutive business days to regain compliance. Trading and the company’s ASX listing remain unaffected. The company will monitor the ADS price and consider options but stated there is no assurance it will regain compliance.
Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026. The poster, titled “Impact of eftilagimod alfa…on lymphocyte activation and survival outcomes in metastatic cancer patients,” is scheduled for 30 May 2026, 1:30 PM–4:30 PM CDT, Poster Board 359, Abstract #2569.
The presentation will report cumulative clinical and translational data across multiple late-stage cancer studies indicating that eftilagimod alfa (efti), an APC activator via MHC class II, induces rapid and sustained lymphocyte activation associated with improved overall survival in metastatic patients.
Immutep (NASDAQ: IMMP) announced the FDA has granted Orphan Drug Designation for eftilagimod alfa (efti) to treat soft tissue sarcoma (STS) on April 15, 2026. The designation may provide regulatory support, tax credits, fee waivers and seven years of market exclusivity if approved.
Immutep cited investigator‑initiated Phase II EFTISARC‑NEO data in 38 evaluable patients showing median tumour hyalinization/fibrosis of 51.5%, above the pre‑specified 35% target and historical ~15% with radiotherapy alone; the study reported immune activation signals and a favourable safety profile without surgery delays.